2012 focused update of the ESC Guidelines for the management of atrial fibrillation
In 2010, when the ESC Guidelines for the Management of Atrial Fibrillation were first issued, it was already realized that an update
would be necessary in 2012 because, for example, European regulatory approvals of several new drugs were anticipated, such as vernakalant and dabigatran. In addition, reports from major clinical trials of the novel oral anticoagulants, such as AVERROES (Apixaban VErsus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment), ROCKET-AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation), and ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation), were expected, paving the way for potentially yet more regulatory approvals.
Clinical outcomes research in AF continues at a fast pace. Also, considerably more clinical experience has been gathered in the fields of anticoagulation, atrial appendage occlusion, antiarrhythmic drug use for cardioversion and rhythm control, and left atrial ablation. These five areas form the bulk of the revisions to our recommendations.
Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.